Cargando…
Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case
Tick-borne diseases affecting humans and animals are on the rise worldwide. Vaccines constitute an effective control measure, but very few are available. We selected Lyme borreliosis, a bacterial infection transmitted by the hard tick Ixodes, to validate a new concept to identify vaccine candidates....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564290/ https://www.ncbi.nlm.nih.gov/pubmed/32825641 http://dx.doi.org/10.3390/vaccines8030463 |
_version_ | 1783595680390971392 |
---|---|
author | Talagrand-Reboul, Emilie Westermann, Benoit Raess, Matthieu A. Schnell, Gilles Cantero, Paola Barthel, Cathy Ehret-Sabatier, Laurence Jaulhac, Benoit Boulanger, Nathalie |
author_facet | Talagrand-Reboul, Emilie Westermann, Benoit Raess, Matthieu A. Schnell, Gilles Cantero, Paola Barthel, Cathy Ehret-Sabatier, Laurence Jaulhac, Benoit Boulanger, Nathalie |
author_sort | Talagrand-Reboul, Emilie |
collection | PubMed |
description | Tick-borne diseases affecting humans and animals are on the rise worldwide. Vaccines constitute an effective control measure, but very few are available. We selected Lyme borreliosis, a bacterial infection transmitted by the hard tick Ixodes, to validate a new concept to identify vaccine candidates. This disease is the most common tick-borne disease in the Northern Hemisphere. Although attempts to develop a vaccine exist, none have been successfully marketed. In tick-borne diseases, the skin constitutes a very specific environment encountered by the pathogen during its co-inoculation with tick saliva. In a mouse model, we developed a proteomic approach to identify vaccine candidates in skin biopsies. We identified 30 bacterial proteins after syringe inoculation or tick inoculation of bacteria. Discovery proteomics using mass spectrometry might be used in various tick-borne diseases to identify pathogen proteins with early skin expression. It should help to better develop sub-unit vaccines based on a cocktail of several antigens, associated with effective adjuvant and delivery systems of antigens. In all vector-borne diseases, the skin deserves further investigation to better define its role in the elaboration of protective immunity against pathogens. |
format | Online Article Text |
id | pubmed-7564290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75642902020-10-26 Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case Talagrand-Reboul, Emilie Westermann, Benoit Raess, Matthieu A. Schnell, Gilles Cantero, Paola Barthel, Cathy Ehret-Sabatier, Laurence Jaulhac, Benoit Boulanger, Nathalie Vaccines (Basel) Article Tick-borne diseases affecting humans and animals are on the rise worldwide. Vaccines constitute an effective control measure, but very few are available. We selected Lyme borreliosis, a bacterial infection transmitted by the hard tick Ixodes, to validate a new concept to identify vaccine candidates. This disease is the most common tick-borne disease in the Northern Hemisphere. Although attempts to develop a vaccine exist, none have been successfully marketed. In tick-borne diseases, the skin constitutes a very specific environment encountered by the pathogen during its co-inoculation with tick saliva. In a mouse model, we developed a proteomic approach to identify vaccine candidates in skin biopsies. We identified 30 bacterial proteins after syringe inoculation or tick inoculation of bacteria. Discovery proteomics using mass spectrometry might be used in various tick-borne diseases to identify pathogen proteins with early skin expression. It should help to better develop sub-unit vaccines based on a cocktail of several antigens, associated with effective adjuvant and delivery systems of antigens. In all vector-borne diseases, the skin deserves further investigation to better define its role in the elaboration of protective immunity against pathogens. MDPI 2020-08-21 /pmc/articles/PMC7564290/ /pubmed/32825641 http://dx.doi.org/10.3390/vaccines8030463 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Talagrand-Reboul, Emilie Westermann, Benoit Raess, Matthieu A. Schnell, Gilles Cantero, Paola Barthel, Cathy Ehret-Sabatier, Laurence Jaulhac, Benoit Boulanger, Nathalie Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case |
title | Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case |
title_full | Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case |
title_fullStr | Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case |
title_full_unstemmed | Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case |
title_short | Proteomic as an Exploratory Approach to Develop Vaccines Against Tick-Borne Diseases Using Lyme Borreliosis as a Test Case |
title_sort | proteomic as an exploratory approach to develop vaccines against tick-borne diseases using lyme borreliosis as a test case |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564290/ https://www.ncbi.nlm.nih.gov/pubmed/32825641 http://dx.doi.org/10.3390/vaccines8030463 |
work_keys_str_mv | AT talagrandreboulemilie proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT westermannbenoit proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT raessmatthieua proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT schnellgilles proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT canteropaola proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT barthelcathy proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT ehretsabatierlaurence proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT jaulhacbenoit proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase AT boulangernathalie proteomicasanexploratoryapproachtodevelopvaccinesagainsttickbornediseasesusinglymeborreliosisasatestcase |